Literature DB >> 22015081

Natural killer T cells in pulmonary disorders.

Matija Rijavec1, Sinisa Volarevic, Katarina Osolnik, Mitja Kosnik, Peter Korosec.   

Abstract

Natural killer T (NKT) cells, a unique subgroup of lymphocytes with features of both T and natural killer (NK) cells, represent a bridge between innate and adaptive immunity. They have the ability to either promote or suppress immune responses. With these immunoregulatory functions, NKT cells have emerged as an important subset of lymphocytes with a protective role in some disorders, such as infections, cancer, and possibly sarcoidosis, and a pathogenic role in others, such as asthma, chronic obstructive pulmonary disease and hypersensitivity pneumonitis. Immunotherapeutic interventions to modulate the immune response by targeting iNKT cell functions has become a challenging field and has shown promising results for the development of new therapies.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 22015081     DOI: 10.1016/S0954-6111(11)70006-3

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  18 in total

Review 1.  Immunotherapy for lung cancer: advances and prospects.

Authors:  Li Yang; Liping Wang; Yi Zhang
Journal:  Am J Clin Exp Immunol       Date:  2016-03-23

2.  NK and NKT-like cells in granulomatous and fibrotic lung diseases.

Authors:  L Bergantini; P Cameli; M d'Alessandro; C Vagaggini; R M Refini; C Landi; M G Pieroni; M Spalletti; P Sestini; E Bargagli
Journal:  Clin Exp Med       Date:  2019-09-04       Impact factor: 3.984

3.  Lysophosphatidic acid generation by pulmonary NKT cell ENPP-2/autotaxin exacerbates hyperoxic lung injury.

Authors:  Martina Nowak-Machen; Martin Lange; Mark Exley; Sherry Wu; Anny Usheva; Simon C Robson
Journal:  Purinergic Signal       Date:  2015-08-26       Impact factor: 3.765

4.  BAL biomarkers' panel for differential diagnosis of interstitial lung diseases.

Authors:  Miriana d'Alessandro; Alfonso Carleo; Paolo Cameli; Laura Bergantini; Anna Perrone; Lucia Vietri; Nicola Lanzarone; Cecilia Vagaggini; Piersante Sestini; Elena Bargagli
Journal:  Clin Exp Med       Date:  2020-01-22       Impact factor: 3.984

5.  T, B, and NKT Cells in Systemic Inflammation in Obstructive Sleep Apnoea.

Authors:  Joanna Domagała-Kulawik; Iwona Osińska; Aleksandra Piechuta; Piotr Bielicki; Tomasz Skirecki
Journal:  Mediators Inflamm       Date:  2015-05-25       Impact factor: 4.711

6.  Development of genetically engineered iNKT cells expressing TCRs specific for the M. tuberculosis 38-kDa antigen.

Authors:  Zhen-Min Jiang; Wei Luo; Qian Wen; Su-Dong Liu; Pei-Pei Hao; Chao-Ying Zhou; Ming-Qian Zhou; Li Ma
Journal:  J Transl Med       Date:  2015-05-07       Impact factor: 5.531

7.  Disposal of iNKT cell deficiency and an increase in expression of SLAM signaling factors characterizes sarcoidosis remission: a 4-year longitudinal study.

Authors:  Katarina Osolnik; Matija Rijavec; Peter Korosec
Journal:  Respir Res       Date:  2014-08-21

Review 8.  Chronic hypersensitivity pneumonitis.

Authors:  Carlos Ac Pereira; Andréa Gimenez; Lilian Kuranishi; Karin Storrer
Journal:  J Asthma Allergy       Date:  2016-09-21

9.  Divergent invariant natural killer T-cell response to sepsis of abdominal vs. non-abdominal origin in human beings.

Authors:  John S Young; Sean F Monaghan; Chun S Chung; William G Cioffi; Alfred Ayala; Daithi S Heffernan
Journal:  Surg Infect (Larchmt)       Date:  2015-02       Impact factor: 2.150

Review 10.  Patient-tailored modulation of the immune system may revolutionize future lung cancer treatment.

Authors:  Marlies E Heuvers; Joachim G Aerts; Robin Cornelissen; Harry Groen; Henk C Hoogsteden; Joost P Hegmans
Journal:  BMC Cancer       Date:  2012-12-05       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.